HCV carriers with normal alanine aminotransferase levels: Healthy persons or severely ill patients?. Dealing with an everyday clinical problem

European Journal of Internal Medicine

Volumn 21, Issue 2, 2010, Pages 57-61

  Puoti, Claudio ^a   Bellis, Lia ^a   Guarisco, Riccardo ^a   Unto, Orlando Dell' ^a   Spilabotti, Lucia ^a   Costanza, Olga Mitidieri ^a  

^a Marino Hospital Rome   (Italy)

Author keywords

Alanine aminotransferase; Biopsy; HCV; Interferon; Normal; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; LIVER ENZYME; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BLOOD EXAMINATION; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE COURSE; ENDOSCOPY; EVIDENCE BASED PRACTICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; LIVER INJURY; PHYSICIAN; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; SCREENING; TREATMENT RESPONSE; VIRUS CARRIER; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

ALANINE TRANSAMINASE; CARRIER STATE; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; MALE;

EID: 77549085428     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2009.12.006     Document Type: Review

References (44)

1. Dore G.J., and Haber P.S. Tell me it ain't so. Patient-to-patient transmission of hepatitis C in an endoscopy clinic. Hepatology 48 (2008) 1333-1335
2. Bisset L., Cossart Y.E., Selby W., West R., Catterson D., O'hara K., et al. A prospective study of the efficacy of routine decontamination for gastrointestinal endoscopes and the risk factors for failure. Am J Infect Control 34 (2006) 274-280
3. Ciancio A., Manzini P., Castagno F., et al. Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. Ann Intern Med 142 (2005) 903-909
4. The Writing Committee on behalf of the Consensus Panel. Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy. Digest Liver Dis 38 (2006) 445-451
5. Ghany M.G., Strader D.B., Thomas D.L., and Seef L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49 (2009) 1335-1373
6. Puoti C., Magrini A., Filippi T., and Aldegheri L. Do symptomless HCV carriers spread infection to their relatives?. Lancet 346 (1995) 893
7. Puoti C. Hepatitis C with normal aminotransferase levels. Dig Dis 25 (2007) 277-278
8. Puoti C., Stati A., and Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal ALT levels. Liver 19 (1999) 104-109
9. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 38 (2003) 529-532
10. Strader D.B., Wright T., Thomas D.L., and Seef L.B. Diagnosis, management and treatment of hepatitis C. AASLD practice guideline. Hepatology 39 (2004) 1147-1171
11. Puoti C., Guido M., Mangia A., Persico M., and Prati D. Committee on HCV carriers with normal alanine aminotransferase levels of the Italian Association for the Study of the Liver. Clinical management of HCV carriers with normal ALT levels. Digest Liver Dis 35 (2003) 362-369
12. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association [AGA] medical position statement on the management of hepatitis C. Gastroenterology 130 (2006) 225-264
13. Marcellin P., Levy S., and Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 26 Suppl 1 (1997) 133S-136S
14. Tassopoulos N.C. Treatment in patients with normal ALT levels. J Hepatol 31 Suppl 1 (1999) 193-196
15. Bacon B.R. Treatment of patients with Hepatitis C and normal serum aminotransferase levels. Hepatology 36 Suppl 1 (2002) S179-S184
16. Puoti C., Castellacci R., and Montagnese F. Hepatitis C virus carriers with normal aminotransferase levels: healthy people or true patients?. Dig Liver Dis 32 (2000) 634-643
17. Martinot-Peignoux M., Boyer N., Cazals-Hatem D., et al. Perspective study of anti-hepatitis C virus-positive patients with persistently normal serum ALT with or without detectable serum HCV RNA. Hepatology 34 (2001) 1000-1005
18. Puoti C., Magrini A., Stati T., et al. Clinical, histological and virological features of Hepatitis C Virus carriers with persistently normal aminotransferase levels. Hepatology 26 (1997) 1393-1398
19. Puoti C., Castellacci R., Montagnese F., et al. Histological and virological features and follow up of hepatitis C virus carriers with normal aminotransferase levels: the Italian Prospective Study of The Asymptomatic C Carriers (ISACC). J Hepatol 37 (2002) 117-123
20. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissiere E., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 27 (1998) 1213-1219
21. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase. Ann Intern Med 137 (2002) 1-10
22. Gordon S.C., Fang J.W.S., Silverman A., McHutchinson J.G., and Albrecht J.K. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 32 (2000) 400-404
23. Jamal M.M., Sony A., Quinn P.G., Wheeler D.E., Arora S., and Johnston D.E. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 30 (1999) 1307-1311
24. Mathurin P., Moussali J., Cadranel J.F., Thibault V., Charlotte F., Dumouchel P., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27 (1998) 868-872
25. Renou C., Halfon P., Pol S., Cacoub P., Jouve E., Bronowicki J.P., et al. Histological features and HLA class II alleles in HCV chronically infected patients with persistently normal alanine aminotransferase levels. Gut 51 (2002) 585-590
26. Hui C.-K., Belaye T., Montegrande K., and Wright T.L. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 38 (2003) 511-517
27. Puoti C., Bellis L., Martellino F., Durola L., Spilabotti L., Dell'Unto O., et al. Occurrence of hepatocellular carcinoma in an apparently healthy HCV patient. Eur J Gastroenterol Hepatol 17 (2005) 1263-1264
28. Persico M., Palmentieri B., Coppola L., Di Giacomo Russo G., Di Marino F., De Sio I., et al. Occurrence of HCC in asymptomatic HCV-related chronic hepatitis. Dig Dis Sci 47 (2002) 2407-2410
29. Pradat P., Alberti A., Poynard T., Esteban J.I., Weiland O., Marcellin P., et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European Collaborative Study. Hepatology 36 (2002) 973-977
30. Rockey D.C., Caldwell S.H., Goodman Z.D., Nelson R.C., and Smith A.D. Liver biopsy. Hepatology 49 (2009) 1017-1044
31. Castera L., Foucher J., Bertet J., Couzigou P., and de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 43 (2006) 373-374
32. Puoti C., Bellis L., Galossi A., Guarisco R., Nicodemo S., Spilabotti L., et al. Antiviral treatment of HCV carriers with normal ALT. Mini Rev Med Chem 8 (2008) 150-152
33. Rumi M.G., De Filippi F., Donato M.F., Del Ninno E., and Colombo M. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 9 (2002) 71-74
34. Serfaty L., Chazouilleres O., Pawlotski J.M., Andreani T., Pellet C., and Poupon R. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 110 (1996) 291-295
35. Sangiovanni A., Morales R., Spinzi G.C., Rumi M.G., Casiraghi A., Ceriani R., et al. Interferon alpha treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 27 (1998) 853-856
36. Rossini A., Ravaggi A., Biasi L., Agostinelli E., Bercich L., Gazzola G.B., et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 26 (1997) 1012-1017
37. Zeuzem S., Diago M., Gane E., Reddy K.R., Pockros P., Prati D., et al. PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a [40KD] and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127 (2004) 1724-1732
38. Snoeck E., Hadziyannis S.J., Puoti C., et al. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alfa-2a (40KD) plus ribavirin. Liver Int 28 (2008) 61-71
39. Puoti C., Pellicelli A., Romano M., et al. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon a-2a and ribavirin: a multicentric study. Liver Int 29 (2009) 1479-1484
40. Zeuzem S., Alberti A., Rosenberg W., Marcellin P., Diago M., Negro F., et al. Management of patients with chronic hepatitis C virus infection and 'normal' aminotransferase activity. Aliment Pharmacol Ther 24 (2006) 1133-1149
41. Alberti A. Towards a more individualised management of HCV patients with initially or persistently normal alanine aminotransferase levels. J Hepatol 42 (2005) 266-274
42. Okanoue T., Itoh Y., Minami M., et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res. 38 (2008) 27-36
43. Puoti C., Guarisco R., Bellis L., and Spilabotti L. Diagnosis, management, and treatment of hepatitis C. Hepatology 50 (2009) 322
44. Puoti C., Bellis L., and Guarisco R. Liver biopsy in Hepatitis C carriers with persistently normal ALT levels. Hepatology 50 (2009) 655-656